Screener
DENTSPLY SIRONA XRAY Wellspect Healthcare — Adjusted research and development (“R&D”) expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by DENTSPLY SIRONA in its filing.
Tagged under the XBRL concept xray:ResearchAndDevelopmentExpenseAdjusted.
The source filing: DENTSPLY SIRONA’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:56 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000818479-26-000255
| (in millions) | Three Months Ended June 30, 2026 / Connected Technology Solutions | Three Months Ended June 30, 2026 / Essential Dental Solutions | Three Months Ended June 30, 2026 / Orthodontic and Implant Solutions | Three Months Ended June 30, 2026 / Wellspect Healthcare | Three Months Ended June 30, 2026 / Total |
|---|---|---|---|---|---|
| Adjusted cost of products sold (a) | 148 | 119 | 86 | 36 | |
| Adjusted selling expenses (b) | 53 | 72 | 59 | 15 | |
| Adjusted general and administrative (“G&A”) expenses (b) | 20 | 20 | 18 | 8 | |
| Adjusted research and development (“R&D”) expenses (c) | 20 | 7 | 13 | 3 | |
| Segment adjusted operating income | $(2) | $158 | $21 | $24 | $201 |
| Reconciling items (income) expense: | |||||
| Unallocated corporate costs (d) | $68 | ||||
| Interest expense, net | 22 |
Item 1 – Financial Statements
FAQ
- What is DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses?
- DENTSPLY SIRONA (XRAY) reported wellspect healthcare — adjusted research and development (“R&D”) expenses of $3M in Q2 2026.
- How has DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses changed year-over-year?
- DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses increased by 50.0% year-over-year, from $2M to $3M.
- What is the long-term trend for DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses?
- Over 3 years (2022 to 2025), DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“R&D”) expenses has grown at a -11.5% compound annual growth rate (CAGR), from $13M to $9M.
- What does wellspect healthcare — adjusted research and development (“R&D”) expenses mean?
- Represents the investment made by the Wellspect Healthcare segment into product innovation, clinical research, and the development of new medical technologies. This metric is a key indicator of the segment's commitment to long-term competitiveness and future product pipeline growth.
Ask your AI about DENTSPLY SIRONA's wellspect healthcare — adjusted research and development (“r&d”) expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude